Population Pharmacokinetics of Lopinavir/Ritonavir: Changes Across Formulations and Human Development From Infancy Through Adulthood-Reference-Cited by-同舟云学术

Population Pharmacokinetics of Lopinavir/Ritonavir: Changes Across Formulations and Human Development From Infancy Through Adulthood

Published:2018-09-25 Issue:12 Volume:58 Page:1604-1617
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharmacology

Author:

Yang Jincheng¹,Nikanjam Mina²,Best Brookie M.¹³,Pinto Jorge⁴,Chadwick Ellen G.⁵,Daar Eric S.⁶,Havens Peter L.⁷,Rakhmanina Natella⁸⁹,Capparelli Edmund V.¹³

Affiliation:

1. Skaggs School of Pharmacy and Pharmaceutical Science; University of California; San Diego CA USA

2. Division of Hematology-Oncology; University of California; San Diego CA USA

3. Division of Host-Microbe Systems and Therapeutics; University of California San Diego School of Medicine; San Diego CA USA

4. Division of Immunology; School of Medicine; Federal University of Minas Gerais; Minas Gerais Brazil

5. Northwestern University Feinberg School of Medicine; Chicago Illinois USA

6. Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center; Los Angeles CA USA

7. Division of Pediatric Infectious Diseases; Medical College of Wisconsin and Children's Hospital of Wisconsin; Milwaukee WI USA

8. Division of Pediatric Infectious Diseases; Children's National Medical Center; The George Washington University; Washington DC USA

9. Elizabeth Glaser Pediatric AIDS Foundation; Washington DC USA

Funder

National Institutes of Health

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/jcph.1293/fullpdf

Reference31 articles.

1. Guidelines for the use of antiretroviral agents in pediatric HIV infection https://aidsinfo.nih.gov/contentfiles/lvguidelines/PedARV_TablesOnly.pdf 2018

2. Sequential population pharmacokinetic modeling of lopinavir and ritonavir in healthy volunteers and assessment of different dosing strategies;Dickinson;Antimicrob Agents Chemother,2011

3. Simultaneous population pharmacokinetic model for lopinavir and ritonavir in HIV-infected adults;Molto;Clin Pharmacokinet,2008

4. Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients;Crommentuyn;Br J Clin Pharmacol,2005

5. Population analysis of weight-, age-, and sex-related differences in the pharmacokinetics of lopinavir in children from birth to 18 years;Jullien;Antimicrob Agents Chemother,2006

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug monitoring of antiretroviral drugs in children with perinatal HIV infection;Acta Biomedica Scientifica;2024-07-22

2. Factors associated with the acceptability of Lopinavir/Ritonavir formulations among children living with HIV/AIDS attending care and treatment clinics in Mbeya and Mwanza, Tanzania;PLOS ONE;2024-01-02

3. HIV-1 reservoir size after neonatal antiretroviral therapy and the potential to evaluate antiretroviral-therapy-free remission (IMPAACT P1115): a phase 1/2 proof-of-concept study;The Lancet HIV;2024-01

4. Inadequate Lopinavir Concentrations With Modified 8-Hourly Lopinavir/Ritonavir 4:1 Dosing During Rifampicin-based Tuberculosis Treatment in Children Living With HIV;Pediatric Infectious Disease Journal;2023-07-20

5. Interactions of the protease inhibitor, ritonavir, with common anesthesia drugs;Pediatric Anesthesia;2022-07-24